Creating a new treatment for non-alcoholic steatohepatitis using a specialized antibody
Development of A Dual Chemokine CCL2/CCL5 Neutralizing Single-domainAntibody for Treating Non-alcoholic Steatohepatitis
This study is testing a new treatment that uses a special type of antibody to help reduce liver inflammation and damage in people with non-alcoholic steatohepatitis (NASH), and it could offer a better option for managing the condition.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oncotrap, INC. NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10761039 on NIH RePORTER |
What this research studies
This research focuses on developing a novel bispecific antibody that targets two specific chemokines, CCL2 and CCL5, which are involved in the progression of non-alcoholic steatohepatitis (NASH). The approach aims to reduce liver inflammation and fibrosis, which are critical in the disease's development. By utilizing a model that simulates NASH, the researchers have shown promising results that suggest this new treatment could be more effective than existing options. Patients may benefit from a new therapeutic option that addresses the underlying causes of their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with non-alcoholic steatohepatitis who have not responded to lifestyle changes.
Not a fit: Patients with other forms of liver disease or those who have advanced liver cirrhosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from non-alcoholic steatohepatitis.
How similar studies have performed: Previous studies have shown success with similar bispecific antibody approaches in treating other conditions, indicating potential for this novel treatment.
Where this research is happening
Chapel Hill, United States
- Oncotrap, INC. — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Gao, Xiang — Oncotrap, INC.
- Study coordinator: Gao, Xiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.